drugset
drugset / Trial / NCT06842134

A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E

NCT06842134 ↗

Phase 1 Completed 16 enrolled Baxter Healthcare Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

This is a phase 1, prospective, single-center, randomized sequence, open label, 2-way crossover study comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E. It is planned to randomize approximately 16 healthy male and female subjects. All study periods will be completed during a single residency, the overall duration of residency will be 11 days (10 nights).

Timeline

Start
2025-01-27
Primary completion
2025-05-22
Completion
2025-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Numeta G16%E Unknown 8.7 mmol Intravenous
Subject Sodium Glycerophosphate Unknown 8.7 mmol Intravenous

Indications

No indication recorded.